ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

platelet rich plasma

Also written as “Platelet-Rich Plasma (PRP) Injections”, “[PRP] platelet rich plasma” and “Autologous PRP Gel and PRP Injection”.

Its studies are mostly in Osteoarthritis · Alopecia · Osteoarthritis, Knee · Diphtheria · Pain, led by 8 companies.

Drug pagePlatelet rich plasma: every studyMany companies study it; this page follows only the 8 they lead. All 326 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 15, 20178 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bioheartits history only10 open or runningphase 1since Mar 15, 2017Mar 15, 2017none ahead
Exactechits history only10 open or runningphase 4since Jan 20, 2009Jan 20, 2009none ahead
Integrant Ptyits history only11 open or runningphase 3since Mar 26, 2025Mar 26, 2025Aug 2027phase 3 · NCT06907121
Kimberly Meathrelits history only11 open or runningearly phase 1since Jul 28, 2026Jul 28, 2026Dec 30, 2027early phase 1 · NCT07739147
PT. Prodia Stem Cell Indonesiaits history only11 open or runningphase 2since Feb 17, 2026Feb 17, 2026none ahead
QC Kinetixits history only10 open or runningphase 2since Feb 6, 2023Feb 6, 2023none ahead
TotipotentRX Cell Therapy Pvt.10 open or runningphase 1since Jan 4, 2017Jan 4, 2017none ahead
Zimmer Biometits history only10 open or runningno phasesince Sep 22, 2008Sep 22, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of TotipotentRX Cell Therapy Pvt. only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 4, 2017First study: phase 1 study in Chronic UlcerFirst studyNCT03026855 · 24 enrolled · India

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study TotipotentRX Cell Therapy Pvt. leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03026855Chronic Ulcer · India1CompletedApr 201624

How it is read

Names in the registry

  • “Platelet-Rich Plasma (PRP) Injections”, 2 entries
  • “[PRP] platelet rich plasma”, 2 entries
  • “Autologous PRP Gel and PRP Injection”, 2 entries
  • “Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma”, 1 entry
  • “Ibuprofen and PRP”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.